Page last updated: 2024-11-08

stigmatellin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

stigmatellin: isolated from myxobacterium Stigmatella aurantiaca; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

stigmatellin A : A member of the class of chromones that is isolated from Stigmatella aurantiaca Sg a15. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID447884
CHEMBL ID486556
CHEBI ID32155
SCHEMBL ID2619157
MeSH IDM0123252

Synonyms (13)

Synonym
stigmatellin
stigmatellin a
91682-96-1
2-[(3s,4s,5s,6s,7e,9e,11e)-4,6-dimethoxy-3,5,11-trimethyltrideca-7,9,11-trienyl]-8-hydroxy-5,7-dimethoxy-3-methylchromen-4-one
AC1L9LCK ,
2-[(3s,4s,5s,6s,7e,9e,11e)-4,6-dimethoxy-3,5,11-trimethyl-7,9,11-tridecatrienyl]-8-hydroxy-5,7-dimethoxy-3-methyl-4h-1-benzopyran-4-one
CHEMBL486556 ,
chebi:32155 ,
2YIU
SCHEMBL2619157
2-[(3s,4s,5s,6s,7e,9e,11e)-4,6-dimethoxy-3,5,11-trimethyltrideca-7,9,11-trien-1-yl]-8-hydroxy-5,7-dimethoxy-3-methyl-4h-chromen-4-one
2-[(3s,4s,5s,6s,7e,9e,11e)-4,6-dimethoxy-3,5,11-trimethyl-trideca-7,9,11-trienyl]-8-hydroxy-5,7-dimethoxy-3-methyl-chromen-4-one
Q7616496

Research Excerpts

Effects

ExcerptReferenceRelevance
"The stigmatellins have been previously described as potent inhibitors of the mitochondrial and photosynthetic respiratory chain and originate from an unusual polyketide synthase assembly line."( Three New Stigmatellin Derivatives Reveal Biosynthetic Insights of Its Side Chain Decoration.
Garcia, R; Hug, JJ; Müller, R; Okoth, DA, 2022
)
1.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
quinol oxidation site inhibitorAn compound that inhibits quinol oxidation sites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
chromonesA chromenone that consists of a 1,4-benzopyrone skeleton and its substituted derivatives thereof.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
olefinic compoundAny organic molecular entity that contains at least one C=C bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
nitrate reduction III (dissimilatory)1219
nitrate reduction VIII (dissimilatory)1915
nitrate reduction IX (dissimilatory)920

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Cytochrome BParacoccus denitrificans PD1222IC50 (µMol)0.13000.13000.13000.1300AID977608
Chain F, Ubiquinol-cytochrome C Reductase Iron-sulfur SubunitParacoccus denitrificans PD1222IC50 (µMol)0.13000.13000.13000.1300AID977608
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID346926Inhibition of Plasmopara viticola cytochrome bc1 complex inoculated in vine plant assessed as lowest drug concentration required to control 100% disease applied to leaf 1 hr prior inoculation measured after 6 to 9 days2008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
The role of molecular modeling in the design of analogues of the fungicidal natural products crocacins A and D.
AID346925Inhibition of Phytophthora infestans cytochrome bc1 complex inoculated in tomato plant assessed as lowest drug concentration required to control 100% disease applied to leaf 1 hr prior inoculation measured after 6 to 9 days2008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
The role of molecular modeling in the design of analogues of the fungicidal natural products crocacins A and D.
AID444027Inhibition of wild type Saccharomyces cerevisiae CK Cytochrome b-c1 complex by spectrophotometry2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Transforming rhinacanthin analogues from potent anticancer agents into potent antimalarial agents.
AID346923Inhibition of Blumeria graminis f. sp. Tritici cytochrome bc1 complex inoculated in wheat plant assessed as lowest drug concentration required to control 100% disease applied to leaf 1 hr prior inoculation measured after 6 to 9 days2008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
The role of molecular modeling in the design of analogues of the fungicidal natural products crocacins A and D.
AID346927Inhibition of Puccinia triticina cytochrome bc1 complex inoculated in wheat plant assessed as lowest drug concentration required to control 100% disease applied to leaf 1 hr prior inoculation measured after 6 to 9 days2008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
The role of molecular modeling in the design of analogues of the fungicidal natural products crocacins A and D.
AID346924Inhibition of Mycosphaerella graminicola cytochrome bc1 complex inoculated in wheat plant assessed as lowest drug concentration required to control 100% disease applied to leaf 1 hr prior inoculation measured after 6 to 9 days2008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
The role of molecular modeling in the design of analogues of the fungicidal natural products crocacins A and D.
AID346928Inhibition of cytochrome bc1 complex in bovine heart mitochondria by NADH oxidase assay2008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
The role of molecular modeling in the design of analogues of the fungicidal natural products crocacins A and D.
AID444029Inhibition of electron transfer from Q(o) site to iron cluster of Saccharomyces cerevisiae CK Cytochrome b-c1 complex assessed as DQH-induced reduction of cyt bc1 complex by redoxdifference spectra2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Transforming rhinacanthin analogues from potent anticancer agents into potent antimalarial agents.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2011Biochimica et biophysica acta, Dec, Volume: 1807, Issue:12
X-ray structure of the dimeric cytochrome bc(1) complex from the soil bacterium Paracoccus denitrificans at 2.7-Å resolution.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (101)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (6.93)18.7374
1990's19 (18.81)18.2507
2000's56 (55.45)29.6817
2010's17 (16.83)24.3611
2020's2 (1.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.97 (24.57)
Research Supply Index4.64 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (3.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other99 (96.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]